Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Invested Capital (2016 - 2025)

Ironwood Pharmaceuticals' Invested Capital history spans 17 years, with the latest figure at -$62.2 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 79.37% year-over-year to -$62.2 million; the TTM value through Dec 2025 reached -$62.2 million, up 79.37%, while the annual FY2025 figure was -$62.2 million, 79.37% up from the prior year.
  • Invested Capital for Q4 2025 was -$62.2 million at Ironwood Pharmaceuticals, up from -$64.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.6 billion in Q4 2023 and bottomed at -$334.1 million in Q1 2025.
  • The 5-year median for Invested Capital is $24.0 million (2021), against an average of $246.0 million.
  • The largest annual shift saw Invested Capital skyrocketed 11667.84% in 2021 before it tumbled 155.55% in 2025.
  • A 5-year view of Invested Capital shows it stood at $722.8 million in 2021, then fell by 9.74% to $652.4 million in 2022, then skyrocketed by 138.32% to $1.6 billion in 2023, then crashed by 119.38% to -$301.3 million in 2024, then skyrocketed by 79.37% to -$62.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Invested Capital are -$62.2 million (Q4 2025), -$64.7 million (Q3 2025), and -$108.8 million (Q2 2025).